ARDSLEY, N.Y.--(BUSINESS WIRE)--Nov. 6, 2012--
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen,
M.D., President and Chief Executive Officer will present at the Lazard
Capital Markets 9th Annual Healthcare Conference on Tuesday,
November 13 at 4:00 pm ET at The Pierre Hotel in New York.
A live audio webcast of the presentation can be accessed under “Investor
Events” in the Investor section of the Acorda website at www.acorda.com,
or you may use the link:
http://wsw.com/webcast/lz13/acor/
Please log in approximately 5 minutes before the scheduled time of the
presentation to ensure a timely connection. An archived version of the
webcast will be available until December 13, 2012 on the Investors
section of www.acorda.com.
About Acorda
Therapeutics
Acorda Therapeutics is a biotechnology company developing therapies for
multiple sclerosis, spinal cord injury and related nervous system
disorders. The Company is commercializing and marketing AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, in the United
States. AMPYRA is a potassium channel blocker approved as a treatment to
improve walking in patients with multiple sclerosis (MS); this was
demonstrated by an improvement in walking speed. AMPYRA was developed
using Alkermes’ Matrix Drug Absorption System (MXDAS®)
technology and is manufactured by Alkermes Pharma Ireland Limited, a
subsidiary of Alkermes plc, based on a supply agreement with Acorda.
Acorda also markets ZANAFLEX
CAPSULES® (tizanidine hydrochloride), a short-acting drug
for the management of spasticity. The Company's pipeline includes a
number of products in development for the treatment, regeneration and
repair of the spinal cord and brain.
Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including Acorda Therapeutics' ability to successfully market and sell
Ampyra in the United States; third party payors (including governmental
agencies) may not reimburse for the use of Ampyra at acceptable rates or
at all and may impose restrictive prior authorization requirements that
limit or block prescriptions; the risk of unfavorable results from
future studies of Ampyra; the occurrence of adverse safety events with
our products; delays in obtaining or failure to obtain regulatory
approval of Ampyra outside of the United States and our dependence on
our collaboration partner Biogen Idec in connection therewith;
competition, including the impact of anticipated potential generic
competition on Zanaflex Capsules revenues; failure to protect Acorda
Therapeutics’ intellectual property, to defend against the intellectual
property claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; the ability
to obtain additional financing to support Acorda Therapeutics'
operations; and, unfavorable results from our research and development
programs. These and other risks are described in greater detail in
Acorda Therapeutics' filings with the Securities and Exchange
Commission. Acorda Therapeutics may not actually achieve the goals or
plans described in its forward-looking statements, and investors should
not place undue reliance on these statements. Forward-looking statements
made in this release are made only as of the date hereof, and Acorda
Therapeutics disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this press release.
Source: Acorda Therapeutics, Inc.
Acorda Therapeutics
Jeff Macdonald, 914-326-5232
jmacdonald@acorda.com
